Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial

Autor: Stuart J. Pocock, Michael A. Nauck, John B. Buse, Qing Ye, Alastair Gray, Heidrun Bosch-Traberg, H. Frimer-Larsen, Johannes F.E. Mann
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Male
medicine.medical_specialty
Visual analogue scale
Endocrinology
Diabetes and Metabolism
Health Status
Injections
Subcutaneous
030209 endocrinology & metabolism
Type 2 diabetes
030204 cardiovascular system & hematology
Placebo
Placebos
03 medical and health sciences
0302 clinical medicine
Endocrinology
Quality of life
Double-Blind Method
EQ-5D
Internal medicine
Surveys and Questionnaires
Internal Medicine
medicine
Humans
Patient Reported Outcome Measures
Stroke
Aged
LEADER
liraglutide
health‐related quality of life
Liraglutide
business.industry
Original Articles
Middle Aged
medicine.disease
Confidence interval
3. Good health
Self Care
Diabetes Mellitus
Type 2
Quality of Life
Original Article
Female
type 2 diabetes
business
patient‐reported outcomes
EQ‐5D
medicine.drug
Follow-Up Studies
Zdroj: Diabetes, Obesity & Metabolism
ISSN: 1463-1326
1462-8902
Popis: Aims To assess health‐related quality of life (HRQoL) in people with type 2 diabetes (T2D) participating in the LEADER cardiovascular outcomes trial using the five‐dimension European Quality of Life questionnaire (EQ‐5D). Materials and methods The EQ‐5D was administered every 12 months in a subset of patients from Canada, Denmark, Germany, Ireland, Italy, Netherlands, Spain, Sweden, the United Kingdom and the United States. We compared changes in utility index scores and visual analogue scale (VAS) scores from baseline to 36 months in participants treated with liraglutide and placebo. We also assessed which complications had the greatest impact on quality of life. Results At 36 months, less deterioration in EQ‐5D utility index score was seen in the liraglutide group (−0.058) than in the placebo group (−0.082; estimated treatment difference [ETD] 0.023, 95% confidence interval [CI] 0.004;0.043; P = 0.020). A smaller decrease in EQ‐5D VAS score was also demonstrated in the liraglutide group (−3.51) vs. the placebo group (−5.45; ETD 1.94, 95% CI 0.32;3.57; P = 0.019). The benefits of liraglutide treatment compared with placebo were driven primarily by shifts in the domains of mobility and self‐care. The most influential events contributing to poorer HRQoL were stroke, heart failure, malignant neoplasm and confirmed hypoglycaemia. Conclusions Liraglutide demonstrated a modest but significant benefit in patient‐reported health status using the EQ‐5D, compared with placebo. This benefit may be of clinical relevance and requires further study.
Databáze: OpenAIRE
Externí odkaz: